drugset / Trial / NCT00016653

Creatine and Glutamine in Steroid-Naive Duchenne Muscular Dystrophy

NCT00016653 ↗

RandomizedDouble-blindTreatment

Summary

This study will help to determine the effectiveness of glutamine and creatine as a possible therapy for DMD. Boys with DMD who are enrolled in this trial will be randomly chosen to receive creatine monohydrate or glutamine or an inactive placebo orally for six months. Once a month during the six-month treatment period, the study participants will have their muscle strength evaluated using manual and computerized testing methods. This study will be conducted at several CINRG Centers throughout the U.S., Belgium, Israel and Puerto Rico. This study is supported by the Muscular Dystrophy Association.

Timeline

Start
2000-06
Primary completion
—
Completion
2006-12

Outcome

Missed primary endpoint

paper Although there was no statistically significant effect of either therapy based on manual and quantitative measurements of muscle strength PMID 15984021 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Creatine Other / unclassified 5 g Oral
Subject Glutamine Other / unclassified 0.6 g/kg Oral